###### Strengths and limitations of this study

-   First study to draw information from Health Research Authority (HRA's) Assessment Review Portal HARP system into one searchable dataset.

-   Anonymised data from the HRA's HARP system can be interrogated with minimal manual intervention.

-   Feasibility study, so limited to data from 2015 only and excluding phase I healthy volunteer studies.

-   Aligning the questions from the XML document was not straightforward.

-   The search terms chosen for the free-text fields were not exhaustive and because it was unfeasible in a pilot to review all applications, the sensitivity and specificity of the text-mining methodology could not be calculated.

Introduction {#s1}
============

The need to improve the quality of clinical research is increasingly understood.[@R1] With a particular focus on clinical studies, the 'gold standard' for evidence-based medicine, there has been a noticeable push towards: improving study protocols[@R1]; developing and implementing newer methodologies, such as adaptive designs[@R2]; involving patients in the design, conduct and management of studies[@R3]; and ensuring that study results are quickly and accurately reported.[@R4]

In order to properly evaluate the current state of clinical research and changes over time, it is clearly necessary to have unfettered access to the research protocols and study results.[@R5] There are a number of limitations in accessing such information. Published evaluations of the state of clinical research are mainly based on the clinical study publication due to the difficulty in obtaining access to unpublished research protocols.[@R7] Research registers are incomplete for many jurisdictions and/or are, like study publications, limited in detail compared with the research protocol. For example, clinicaltrials.gov[@R8] has good coverage of clinical studies in North America, where registration of clinical trials is mandatory. The WHO International Clinical Trials Registry Portal[@R9] provides access to 15 different regional or national registries, but both have markedly less detail than in the study's research protocol. Published evaluations of the literature are likely affected by publication bias and there are often discrepancies between research publications and their underpinning protocols.[@R10]

The ability to analyse a large database of application forms, each of which contain very detailed information taken directly from the research protocol, would enable researchers to perform a detailed examination of the characteristics of clinical studies, particularly those necessary for generating reliable evidence. This would aid understanding of how study characteristics change over time and across therapeutic areas, as well as the progress of initiatives to improve the quality and relevance of clinical studies.[@R11] Therefore, we approached the UK Health Research Authority (HRA), which oversees national ethical review of health research conducted within the National Health Service (NHS). With the support of the HRA and having signed the appropriate confidentiality declarations, we developed a pilot project to determine the feasibility of interrogating with minimal manual intervention the data contained in HARP (HRA Assessment Review Portal). HARP is a web-based management information system used by the HRA for all research ethics applications that require NHS REC (National Health Service Research Ethics Committee) review and/or HRA approval. We negotiated access to data on clinical studies submitted in 2015. The extract had personal data and organisational identifiers removed by HRA and did not include phase I healthy volunteer studies.

Our pilot focused on automatically summarising the characteristics of clinical studies, including therapeutic area, blinding, randomisation, use of Independent Data Monitoring Committee (IDMC), patient and public involvement (PPI) in the research, dissemination of the study results and use of new methodologies such as adaptive designs.

Methods {#s2}
=======

The HRA collects applications for REC 'approval' (a favourable opinion) through the Integrated Research Application System (IRAS)[@R16] and stores them in HARP. IRAS is a web-based system used to capture the information required by review bodies in the UK, including the Medicines and Healthcare Products Regulatory Agency and HRA. When the forms are completed, IRAS saves the results as an XML document. XML is a commonly used file format that stores structured data in plain text. The XML document can be used to generate PDF copies of the required forms and to repopulate the online web tool so users can later edit their applications.

Once the appropriate permissions were agreed, the HRA provided us with anonymised applications for clinical studies submitted for review from 2014 to 2016, excluding phase I healthy volunteer studies. For this pilot, we wished to focus on the extraction of clinical study characteristics of interest from the PDF versions of the HRA forms underlying the IRAS application system. We were provided with an incomplete mapping between the questions on the PDF and the data stored in the XML document, such that many questions relevant to our study were not immediately labelled; nor was it apparent which questions were effectively switched on and off for applicants in completing the system's initial filter questions for their application. Therefore, we reverse-engineered the structure of the data in IRAS to determine which XML tags were responsible for creating the content we wanted to extract from the XML files to study.

The IRAS tool has been updated over time; not all of applications were created using the same version. Although the majority (91%) of the XML documents were created with one version (the latest version of the tool in the dataset), eight different versions were present in the dataset we received. We were not provided with the documentation detailing the ways in which the versions differed; we had access only to the latest version. Our inspection of the data indicated that the differences relevant to this pilot study were minor and we corrected for these when they were detected; however, there may be some undetected differences where the distinction between versions was important for our study.

For our pilot project, we chose to collect information on: the number of randomised controlled trials (RCT); the trial phase; the therapeutic area; the number of clinical trials of investigational medicinal products (CTIMPs --- trials that require registration with regulatory body); the research method used (eg, RCT, feasibility/pilot study, blinding); the use of blinding; the use of systematic or formal literature reviews in planning the study; the use of adaptive or Bayesian designs; the use of a data monitoring committee; the plans for dissemination of findings; and the role of PPI in aspects of the research. Success would be measured in terms of our ability to access the information and generate descriptive summaries with minimal need for manual data reviews.

The data for our target areas were either held in multiple choice questions that we could identify and summarise or in free-text fields from which information needed to be determined and extracted. For those questions, we preprocessed the text using Spacy (<https://spacy.io/>), a natural language processing (NLP) package for Python. This involved identifying sentence boundaries and performing morphological analysis to convert words into their canonical dictionary form. We then used regular expressions to match phrases we were interested in, ignoring differences relating to spacing, hyphenation and capitalisation; Roman numerals were standardised to Latin numbers. For example, when looking for evidence that a systematic review was either performed or an existing review used during the study planning process, we searched for phrases such as 'systematic review', 'reviewed systematically', 'literature review', 'evidence review' and 'evidence-based review' in the answers provided to the relevant questions on the form, or instances where these words were used near each other, where 'near' was defined as being within three words. For adaptive designs, we employed the US Food and Drug Administration (FDA) definition, namely 'a study that includes a prospectively planned opportunity for modification'.[@R17] We extracted the sentence containing the target phrase as well as one sentence before and after into a separate document. These textural extracts were then reviewed by the authors to identify true and false positives.

The data extracted from the separate XML files were collated into one dataset and descriptive analyses of this dataset were done with Stata.

Results {#s3}
=======

We received (30 June 2016) the XML files for 1814 application records submitted for ethical review during the period specified, and extracted by HRA from the IRAS system. Of these, 1659 (92%) were from 2015, 154 (9%) from 2014 and 1 was from 2016. Three records were corrupted and could not be processed. In discussion with HRA, we discarded some records to remove duplicates. We kept one of four entries for the WHEAT trial which had been sent to multiple committees as part of research on consistency of REC opinions.[@R18] We discarded one of two entries for a further study, which was initially given a favourable opinion and then submitted additionally to a specialist REC in Scotland (again, favourably). Thirty-two further records were discarded that initially had an unfavourable opinion before re-submission as a (near) identical, separate application for review. We discarded the first applications and kept the re-submissions, regardless of the subsequent review's outcome. Therefore, our dataset included 1775 studies.

The filter questions switched off, for some applications, questions in which we were interested. For example, trial phase was only recorded for CTIMPs and the use of data monitoring committees was infrequently recorded. Furthermore, the use of blinding was not sufficiently well captured in the system to allow us to present reliable data.

A total of 963/1775 (54%) of the applications were stated as being RCTs. [Table 1](#T1){ref-type="table"} describes the disease setting, research method, CTIMP and REC opinion by whether they were an RCT. The most common research area, using the categorisation of the IRAS system, was cancer, followed by cardiovascular, musculoskeletal and respiratory diseases; around one-third of records specified more than one area. This is broadly consistent with previous reviews.[@R19] Around one-fifth of RCTs were pilot studies; one-third of records were employing more than one method. The REC gave a favourable opinion to the vast majority of applications (1740/1775, 98%), but required additional information for most of these 1323/1740 (75%).

###### 

Overview of research activities submitted for REC approval

  Characteristic                           RCT     Other   Total                 
  ---------------------------------------- ------- ------- ------- ------ ------ ----
  N                                        963             812            1775   
  **Therapeutic area\***                                                         
   Cancer                                  168     17      192     24     360    20
   Cardiovascular                          94      10      94      12     188    11
   Musculoskeletal                         97      10      30      4      162    9
   Respiratory                             97      10      30      4      159    9
   Paediatrics                             56      6       30      4      148    8
   Neurological                            73      8       30      4      145    8
   Mental health                           66      7       30      4      117    7
   Inflammatory and immune system          72      7       30      4      113    6
   Oral and gastrointestinal               64      7       30      4      113    6
   Blood                                   44      5       67      8      111    6
   Diabetes                                58      6       38      5      96     5
   Infection                               55      6       30      4      92     5
   Renal and urogenital                    39      4       30      4      82     5
   Generic health relevance                46      5       30      4      76     4
   Metabolic and endocrine                 32      3       30      4      70     4
   Dementias and neurodegenerative         27      3       36      4      63     4
   Skin                                    36      4       30      4      57     3
   Reproductive health and childbirth      30      3       30      4      56     3
   Stroke                                  27      3       30      4      53     3
   Eye                                     24      2       28      3      52     3
   Injuries and accidents                  22      2       30      4      36     2
   Congenital disorders                    10      1       20      2      30     2
   Ear                                     6       1       7       1      13     1
  **Count of therapeutic areas claimed**                                         
   None                                    52      5       49      6      101    6
   1                                       660     69      495     61     1155   65
   2                                       201     21      200     25     401    23
   3                                       29      3       49      6      78     4
   ≥4                                      21      2       19      2      40     2
  **Research methods used\***                                                    
   RCT                                     963     100     2       0      965    54
   Feasibility/pilot study                 177     18      300     37     477    27
   Questionnaire                           98      10      139     17     237    13
   Cohort observation                      23      2       161     20     184    10
   Qualitative research                    90      9       76      9      166    9
   Controlled trial, no randomisation      3       0       157     19     160    9
   Laboratory study                        30      3       47      6      77     4
   Case series/case note review            7       1       45      6      52     3
   Cross-sectional study                   4       0       31      4      35     2
   Case--control study                     5       1       25      3      30     2
   Database analysis                       8       1       17      2      25     1
   Epidemiology                            7       1       5       1      12     1
   Meta-analysis                           0       0       0       0      0      0
   Other                                   68      7       269     33     337    19
  **Count of research methods used**                                             
   1                                       641     67%     522     64     1163   66
   2                                       192     20      160     20     352    20
   3                                       73      8       97      12     170    10
   4                                       48      5       25      3      73     4
   5                                       7       1       7       1      14     1
   6                                       2       0       1       0      3      0
  **CTIMP**                                                                      
   Unlicensed                              315     33      189     23     504    28
   New use                                 146     15      70      9      216    12
   Within SmPC                             66      7       26      3      92     5
   Other                                   10      1       5       1      15     1
   *Any of these*                          *515*   *53*    *284*   *35*          
  **Involves ionising radiation**                                                
   Yes                                     666     69      582     72     1248   71
   No                                      297     31      222     28     519    29
   *Missing*                               0       NA      8       NA     8      NA
  **REC opinion**                                                                
   Favourable                              942     98      798     98     1740   98
    Favourable                             200     21      217     27     417    23
    Favourable (extra info)                742     77      581     72     1323   75
   Unfavourable                            21      2       14      2      35     2

\*Not mutually exclusive.

CTIMP, clinical trials of investigational medicinal product; RCT, randomised controlled trial; REC, Research Ethics Committee; SmPC, summary of product characteristics.

Over half of the RCTs (515/963, 53%) were CTIMPs, of which 315/515 (61%) were CTIMPs of unlicensed products, 146/515 (28%) licensed CTIMPs in a new setting and 66/515 (13%) CTIMPs used according to their summary of product characteristics (SmPC); the categories were not mutually exclusive. Over a third (284/812, 35%) of the other studies (not RCTs) were also CTIMPs.

[Table 2](#T2){ref-type="table"} describes the plans in design and dissemination. Most RCTs (895/963, 93%) were not recorded as being preceded by a formal systematic review of the literature. Only 15 (2%) RCTs were detectably designed under a Bayesian framework; 20 (2%) were detectable as having an adaptive design. There were 34 cluster randomised and 5 stepped wedge trials, overall. Six hundred fourteen (63%) RCTs were requesting new biological samples; 120 (12%) RCTs were seeking access to previous biological samples.

###### 

Issues in design and dissemination in all entries

  Characteristic                              RCT   Other   Total               
  ------------------------------------------- ----- ------- ------- ---- ------ ----
  N                                           963           812          1775   
  **Review of data as part of development**                                     
   Neither                                    895   93      759     93   1654   93
   Systematic review only                     38    4       32      4    70     4
   Meta-analysis only                         18    2       13      2    31     2
   Both                                       12    1       8       1    20     1
  **Design characteristics**                                                    
   Neither                                    926   96      778     96   1704   1
   Adaptive design                            20    2       9       1    29     2
   Bayes design                               15    2       24      3    39     2
   Both                                       2     0       1       0    3      0
   Cluster randomised                         26    3       8       1    34     2
   Stepped wedge                              3     0       2       0    5      0
  **Sample collection\***                                                       
   Taking new samples                         614   64      422     52   1036   58
   Accessing stored samples                   120   12      110     14   230    13
  **Plans for dissemination†**                                                  
   Peer-reviewed scientific journal           912   95      755     93   1667   94
   Conference presentation                    869   90      716     8    1585   89
   Internal report                            641   67      526     65   1167   66
   Publication on website                     536   56      367     45   903    51
   Submission to regulatory authority         475   49      352     43   827    47
   Other publication                          239   25      178     22   417    23
   Access to raw data                         191   20      133     16   114    6
   Other                                      0     0       3       0    324    18
   No plans to report or disseminate                                     3      0

\*Not asked for non-regulatory RCTs.

†Not mutually exclusive.

RCT, randomised controlled trial.

The large majority of research (1667/1775, 94%) was planned for dissemination in the peer-reviewed literature and most (1585/1775, 89%) were planned for conference presentations. A total of 475/963 (49%) RCTs and 352/812 (43%) other studies were planned for submission to regulatory authorities. A small number, 114/1775 (6%), were planning to offer raw data to external applicants as a key form of dissemination.

[Table 3](#T3){ref-type="table"} notes the reported patients and public involvement (PPI) using the categories specified by IRAS. A total of 726/1775 (41%) of studies claim PPI in the design and 659/1775 (37%) claim planned PPI in dissemination of the findings. PPI engagement in undertaking and management of the research was less common, and few studies (147/1775, 8%) involved planned PPI in analysis. Around one-third of studies involve PPI in two or more of these IRAS-defined areas.

###### 

Reported PPI

  Characteristic                        RCT   Other   Total               
  ------------------------------------- ----- ------- ------- ---- ------ ----
  N                                     963           812          1775   
  **Areas of PPI activity\***                                             
   Design of the research               403   42      323     40   726    41
   Dissemination of findings            375   39      284     35   659    37
   Undertaking the research             242   25      219     27   461    26
   Management of the research           225   23      129     16   354    20
   Analysis of results                  72    7       75      9    147    8
  **Number of areas of PPI activity**                                     
   None                                 389   40      302     37   691    39
   1                                    205   21      209     26   414    23
   2                                    139   14      117     14   256    14
   3                                    125   13      93      11   218    12
   4                                    66    7       37      5    103    6
   All                                  39    4       32      4    71     4

\*Not mutually exclusive.

PPI, patient and public involvement.

[Table 4](#T4){ref-type="table"} shows within CTIMPs the similarities and differences across the phase of research. Trial phase was asked as a series of separate yes/no questions for phase I, II, III and IV. These were not mutually exclusive. For the purpose of summarising, we selected the highest level if more than one option was selected. Early phase trials were more likely to be designed within a Bayesian framework; phase III trials most often reported the use of a placebo and the use of an Independent Data Monitoring Committee; phase IV trials were least likely to be submitted to a regulatory authority or put on a website, but most often reported PPI in all five broad areas.

###### 

Characteristics of the CTIMPs by trial phase

  Trial phase\*                               Ph I   Ph II   Ph III   Ph IV   Total                            
  ------------------------------------------- ------ ------- -------- ------- ------- ---- ------ ---- ------- ----
  All entries, N                              99             287              324          98          808     
  **Design characteristics**                                                                                   
   Neither                                    86     89      261      93      303     94   90     94   740     93
   Adaptive                                   1      1       7        2       13      4    3      3    24      3
   Bayes                                      10     10      12       4       5       2    2      2    29      4
   Both                                       0      0       2        1       0       0    1      1    3       0
   Cluster randomised                         0      0       0        0       0       0    0      0    0       0
   Stepped wedge                              0      0       0        0       0       0    0      0    0       0
   Involves placebo                           21     22      123      44      163     51   25     26   332     42
  **Independent data monitoring committee**                                                                    
   No                                         40     82      84       59      61      42   46     78   231     58
   Yes                                        9      18      59       41      84      58   13     22   165     42
   *Missing*                                  *8*            *139*            *176*        *37*        *400*   
  **Methods of dissemination**                                                                                 
   Peer-reviewed scientific journal           86     89      265      94      290     90   93     97   86      89
   Submission to regulatory authority         85     88      215      76      272     85   48     50   85      88
   Conference presentation                    82     85      253      90      271     84   89     93   82      85
   Internal report                            71     73      212      75      259     81   60     63   71      73
   Publication on website                     56     58      161      57      203     63   45     47   56      58
   Other publication                          26     27      76       27      92      29   17     18   26      27
   Access to raw data                         8      8       12       4       25      8    8      8    8       8
   Other                                      12     12      47       17      48      15   18     19   12      12
   No plans to report or dissemination        0      0       0        0       2       1    0      0    0       0
  **Areas of PPI activity†**                                                                                   
   Design of the research                     26     27      82       29      39      12   50     52   26      27
   Management of the research                 10     10      34       12      28      9    31     32   10      10
   Undertaking the research                   14     14      47       17      36      11   29     30   14      14
   Analysis of results                        1      1       15       5       7       2    12     13   1       1
   Dissemination of findings                  20     21      74       26      64      20   44     46   20      21
   None of the above                          53     55      149      53      223     69   35     36   460     58
  **REC opinion**                                                                                              
   Favourable                                 97     98      277      97      318     98   93     95   785     97
    Favourable                                14     14      51       18      40      12   15     15   120     15
    Favourable (after extra info)             83     84      226      79      278     86   78     80   665     82
   Unfavourable                               0      0       5        2       3       1    3      3    11      1

\*Trial phase calculated.

†Not mutually exclusive.

CTIMP, clinical trials of investigational medicinal product; PPI, patient and public involvement; REC, Research Ethics Committee.

[Table 5](#T5){ref-type="table"} shows the outcome of the manual review of the extracted free-text fields. Accuracy, defined as number of true positives divided by overall total ranged from 43% for adaptive designs to 100% for stepped wedge. The false positives related to studies described as 'phase 1/2' or 'phase 2/3', but with no evidence of an adaptive step, for example, phase 1/2 was often used to describe a classical pharmacokinetic study in patients rather than healthy volunteers; the database did not contain healthy volunteer studies. For 'systematic review' and 'meta-analysis', the search often picked up references to previous studies and not the planned study.

###### 

Review of possible search terms

  ----------------------------------------------------------------------------------------------
  Design element\                 Performance of search term\*                            
  Search term                                                                             
  ------------------------------- ------------------------------ ----- ------ ----- ----- ------
  **Systematic review**                                                                   

   Review (near) systematically   2                              0     100    2     0     100

   Evidence (near) review         4                              1     80     4     1     80

   Systematic (near) review       98                             39    72     58    23    72

   Literature (near) review       29                             13    69     26    12    68

   *Evidence-based review*        *0*                            *0*   *NA*   *0*   *0*   *NA*

   Summary\*†                     133                            53    72     90    36    71

  **Meta-analysis**                                                                       

   Pooled analysis                2                              0     100    2     0     100

   Meta-analysis                  77                             31    71     49    19    72

   *Integrated analysis*          *0*                            *0*   *NA*   *0*   *0*   *NA*

   Summary\*†                     79                             31    72     51    19    73

  **Adaptive design**                                                                     

   Adaptive design                19                             0     100    13    0     100

   Adaptive randomisation         8                              0     100    5     0     100

   Continual reassessment         2                              0     100    1     0     100

   Sample size re-estimation      15                             0     100    9     0     100

   Seamless design                1                              0     100    1     0     100

   Phase I/II                     4                              43    9      3     37    8

   Phase II/III                   2                              25    7      2     23    8

   *CRM design*                   *0*                            *0*   *NA*   *0*   *0*   *NA*

   *Drop-the-loser*               *0*                            *0*   *NA*   *0*   *0*   *NA*

   *MAMS design*                  *0*                            *0*   *NA*   *0*   *0*   *NA*

   *Multiarm multistage*          *0*                            *0*   *NA*   *0*   *0*   *NA*

   *Pick-the-winner*              *0*                            *0*   *NA*   *0*   *0*   *NA*

   Summary\*†                     51                             68    43     31    60    34

  **Bayes**                                                                               

   Bayes                          83                             2     98     42    1     98

   Summary\*†                     83                             2     98     42    1     98

  **Cluster RCT**                                                                         

   Cluster RCT                    26                             0     100    11    0     100

   Control cluster                6                              0     100    4     0     100

   Randomised cluster             2                              0     100    1     0     100

   Cluster random                 46                             1     98     30    1     97

   Summary\*†                     80                             1     99     34    1     97

  **Stepped wedge**                                                                       

   Step (near) wedge              1                              0     100    1     0     100

   Stepped (near) wedge           16                             0     100    5     0     100

   Summary\*†                     17                             0     100    5     0     100
  ----------------------------------------------------------------------------------------------

NB The table reports on whether each search term accurately identified a specific design element of the study in selected free-text fields. All variations of the spelling, capitalisation, hyphenation and so on were covered in the search terms used.

\*The left side of the table separately considers each sentence which matched a search term accurately identified the design property. There were 613 such sentences. The Summary row in each subsection is the sum of the constituent search terms.

†The right side of the table separately considers whether any sentence in a study matching a search term accurately identified the design property. Some studies matched a search term repeatedly, therefore the numbers are smaller. The Summary row in each subsection reflects a search across all of its constituent search terms. Note that some studies matched more than one search term in a subsection, so the Summary row may not be the sum of the rows above for example, a study that uses both 'cluster random' and 'control cluster' would appear only once in the Summary row, and would appear separately in the 'cluster random' and 'control cluster' rows.

CRM, continual reassessment method; MAMS, multi-arm multi-stage; RCT, randomised controlled trial.

Discussion {#s4}
==========

We achieved our primary feasibility aim of negotiating access to the centralised UK approvals system and devising a way of extracting information from a series of separate XML files. We anticipate that the programmes we developed could extract further pertinent points of information with minimal manual involvement. We were also able to achieve our primary descriptive aim of systematically reporting on the state of clinical research in the UK over around 1 year, focused on 2015.

We found that nearly 1000 RCTs were submitted for approval in the UK during that period and \>800 other studies. A key message is the volume of research activity in the UK, with the country demonstrably research active. The majority of applications received a favourable opinion but most required further information first, suggesting that applications could be better completed, saving time and effort for all parties.

It was notable that the reported use of adaptive designs was low and was not markedly different from earlier estimates.[@R19] This is disappointing, as many members of this design family have scope to reduce time to answer and/or reduce the average cost per answer, particularly by moving away early from treatment approaches that are not likely to improve outcomes sufficiently for patients.[@R21] However, Bayesian approaches have penetrated 10% of early phase CTIMPs. The reported use of IDMCs for phase III CTIMPs was, perhaps, low at 58%, but this is a substantial increase over the prevalence in trials published in high impact-factor journals in 1990 and 2000.[@R22] Involvement of patients and the public in various aspects of research is increasingly seen as important, but reported rates of engagement were quite low: more than half of studies had no PPI involvement.[@R23] Cursory review of the free-text fields associated with these PPI categories suggests that some applicants may have been a little generous in choosing to select a particular category, suggesting that the numbers we report may be overestimates. Other comments suggest that PPI is not needed, perhaps reflecting that the value of PPI is yet to be recognised by some researchers.[@R3] Further research in this area is required.

Most but not all studies were planned for publication; there is still some way to go on this transparency aim. That raw data would be made available for some studies is encouraging and we hope that this will increase with time for appropriate projects from qualified researchers.[@R24]

Extracting the information from the HRA system was more effortful than expected. Moreover, important characteristics of clinical trials like blinding could not be analysed and certain search terms clearly had limitations. The issue of blinding is particularly important, as it is one of the desirable characteristics in generating reliable evidence from clinical trials.[@R11] However, now that we have completed this feasibility step, it is possible for future research projects to access an expanded dataset and work with the HRA to organise the database in a way that will facilitate its analysis. Access to several years of data would allow researchers, as well as the HRA itself, to examine the progress of initiatives to improve the quality of clinical research, such as those designed to encourage PPI and publication of clinical trial results.[@R13] We would also encourage the HRA to adopt standard definitions to describe the characteristics of clinical trials, as done in the USA.[@R25] Confusion over the definition of terms greatly complicates efforts to automatically analyse clinical research.

Our pilot work has some limitations. We had no straightforward way of aligning the questions in the PDF document with the information stored in the XML document. Perhaps if we had negotiated access to the backend software used by IRAS to generate these PDF forms, we may have been able to do this automatically; instead, we needed to reverse-engineer the IRAS system in order to figure out which XML tags were responsible for creating the content we wanted to study. Not all of the applications had been created using the same version of the IRAS tool.[@R16] Although a large majority of the documents were created using the latest version of the tool, eight different versions were present in the dataset we received. We did not receive any guidance on the ways in which one version of the tool differed from another version, and we only had access to the latest version. We made efforts to determine the specific situations in which questions were not asked rather than asked but not answered, in order to make this distinction ourselves, though ideally this could be indicated directly in the XML dataset. The labelling of missing answers and inactivated questions was not consistent. There is scope for applicants to misunderstand the questions and misrepresent the data. For example, three trials were noted as using RCT methodology but answered 'no' to the question: 'Will participants be allocated to groups at random?' We checked the data and found these were not actually RCTs; we included them with the 'other studies'. Likely this error by the applicants activated or de-activated some questions inappropriately. In this example, the RCT method question actually asked about randomisation of individuals and these three applicants who submitted cluster randomised trials had answered this question inconsistently. Finally, the search terms chosen for the free-text fields were not exhaustive and because it was unfeasible in a pilot to review all applications, the sensitivity and specificity of the free-text extraction could not be calculated.

Some interesting information was held only in the free-text fields. We used standard methods to extract this information using automation supplemented by manual checking. There is a wealth of free-text information, which through the application of text-mining techniques could provide incredibly valuable insights into the characteristics of health research. For this pilot study, we did not have the resources to review all of the questions and we particularly could not spend time reading free-text fields. Therefore, we felt obliged not to correct categorical questions if we noticed they were contrasted by free-text; however, a fully-resourced study could do this. For example, we noticed at least one entry, which ticked boxes for PPI engagement and expanded on this by claiming that, as doctors, they knew what patients wanted and did not need to trouble patients for their time on these aspects.

In conclusion, we have demonstrated that anonymised data from the HRA's research system are accessible and can be queried for information. We strongly encourage the development of fully resourced collaborative projects to delve more deeply into this data. We believe that it is imperative that the characteristics of clinical research in the UK are understood, as these underpin clinical guidance. Finally, there are many ongoing initiatives to improve the quality of clinical research, but only by fully understanding the state of, and changes to, the research profile of the UK, can we appreciate their impact.
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